15-45116587-T-TA
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000323030.6(DUOXA2):c.413dup(p.Tyr138Ter) variant causes a stop gained, frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000502 in 1,613,946 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000079 ( 0 hom., cov: 34)
Exomes 𝑓: 0.000047 ( 0 hom. )
Consequence
DUOXA2
ENST00000323030.6 stop_gained, frameshift
ENST00000323030.6 stop_gained, frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 3.10
Genes affected
DUOXA2 (HGNC:32698): (dual oxidase maturation factor 2) This gene encodes an endoplasmic reticulum protein that is necessary for proper cellular localization and maturation of functional dual oxidase 2. Mutations in this gene have been associated with thyroid dyshormonogenesis 5.[provided by RefSeq, Feb 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 15-45116587-T-TA is Pathogenic according to our data. Variant chr15-45116587-T-TA is described in ClinVar as [Pathogenic]. Clinvar id is 225344.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DUOXA2 | NM_207581.4 | c.413dup | p.Tyr138Ter | stop_gained, frameshift_variant | 4/6 | ENST00000323030.6 | NP_997464.2 | |
DUOXA2 | XM_017022180.2 | c.464dup | p.Tyr155Ter | stop_gained, frameshift_variant | 4/6 | XP_016877669.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DUOXA2 | ENST00000323030.6 | c.413dup | p.Tyr138Ter | stop_gained, frameshift_variant | 4/6 | 1 | NM_207581.4 | ENSP00000319705 | P1 | |
DUOXA2 | ENST00000491993.2 | c.*480dup | 3_prime_UTR_variant, NMD_transcript_variant | 4/6 | 1 | ENSP00000454110 | ||||
DUOXA2 | ENST00000350243.10 | n.693dup | non_coding_transcript_exon_variant | 4/5 | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000788 AC: 12AN: 152228Hom.: 0 Cov.: 34
GnomAD3 genomes
AF:
AC:
12
AN:
152228
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000236 AC: 59AN: 249472Hom.: 0 AF XY: 0.000177 AC XY: 24AN XY: 135380
GnomAD3 exomes
AF:
AC:
59
AN:
249472
Hom.:
AF XY:
AC XY:
24
AN XY:
135380
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000472 AC: 69AN: 1461718Hom.: 0 Cov.: 79 AF XY: 0.0000371 AC XY: 27AN XY: 727172
GnomAD4 exome
AF:
AC:
69
AN:
1461718
Hom.:
Cov.:
79
AF XY:
AC XY:
27
AN XY:
727172
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000788 AC: 12AN: 152228Hom.: 0 Cov.: 34 AF XY: 0.0000807 AC XY: 6AN XY: 74364
GnomAD4 genome
AF:
AC:
12
AN:
152228
Hom.:
Cov.:
34
AF XY:
AC XY:
6
AN XY:
74364
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2
AN:
3478
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Thyroglobulin synthesis defect Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PVS1+PM2_Supporting+PM3_VeryStrong+PP4 - |
Pathogenic, criteria provided, single submitter | reference population | Soonchunhyang University Bucheon Hospital, Soonchunhyang University Medical Center | Mar 18, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 09, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at